logo
  

Murphy Oil Loss Narrower Than Estimates

Murphy Oil Corp (MUR) on Wednesday reported second-quarter net loss of $73.8 million or $0.42 per share compared with a profit of $129.4 million or $0.72 per share last year.

Excluding items, adjusted loss for the quarter was $0.48 per share compared with a profit of $0.90 per share a year ago.

Revenues for the quarter were lower at $738.3 million compared with $1.34 billion in the prior year.

Analysts polled by Thomson Reuters estimated a loss of $0.55 per share on revenues of $697.7 million for the quarter. Analysts' estimates typically exclude special items.

Murphy said its production for the second quarter averaged 201,952 boepd, ahead of its guidance of 197,000 boepd, primarily attributed to new well performance in the Eagle Ford Shale and risked startup of the Medusa expansion project.

For the third quarter, the company expects production of 200,000 boepd.

For full year 2015, it increased production guidance to a range of 200,000 to 208,000 boepd, from prior range of 195,000 boepd to 207,000 boepd.

Capital expenditure is still forecast to be $2.3 billion for 2015.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT